scholarly journals Understanding Barriers to Adherence to Optimal Treatment of Elevated Blood Pressure and Hypertension—Insights From Primary Care

2021 ◽  
Vol 4 (12) ◽  
pp. e2138651
Author(s):  
Harry H. X. Wang ◽  
Stewart W. Mercer
Diabetes Care ◽  
2006 ◽  
Vol 29 (12) ◽  
pp. 2580-2585 ◽  
Author(s):  
P. C. Hicks ◽  
J. M. Westfall ◽  
R. F. Van Vorst ◽  
C. Bublitz Emsermann ◽  
L. M. Dickinson ◽  
...  

2019 ◽  
Vol 4 (5) ◽  
pp. e187 ◽  
Author(s):  
Michael L. Rinke ◽  
Hardeep Singh ◽  
Tammy M. Brady ◽  
Moonseong Heo ◽  
Steven W. Kairys ◽  
...  

2008 ◽  
Vol 22 (11) ◽  
pp. 755-760 ◽  
Author(s):  
C Thomas ◽  
G C Wood ◽  
R D Langer ◽  
W F Stewart

1960 ◽  
Vol XXXIV (III) ◽  
pp. 411-429 ◽  
Author(s):  
Melvin J. Fregly ◽  
Kenneth M. Cook

ABSTRACT The anti-thyroid drugs, thiouracil, propylthiouracil, and methimazole, prevented both development of elevated blood pressure and cardiac hypertrophy usually accompanying kidney encapsulation with latex envelopes. These drugs also reduced elevated blood pressure of rats with hypertension of 13 to 40 weeks' duration prior to drug administration. Addition of desiccated thyroid powder to diet containing an anti-thyroid drug overcame the anti-hypertensive effect of the latter. Withdrawal of thyroid powder only was followed by return of blood pressure to previous low level within 3 weeks. The results suggest that the anti-hypertensive effect of these drugs is related directly to the hypothyroidism produced rather than to extrathyroidal effects of the drugs. Comparison of potencies of the 3 drugs in terms of anti-hypertensive effect, inhibition of growth rate, increase in testicular size, and increase in thyroid size suggests that propylthiouracil and methimazole are equally potent per unit weight of drug. Thiouracil has approximately half the potency of the other two.


Sign in / Sign up

Export Citation Format

Share Document